On September 26, 2024, Snehal Patel, CEO, CFO, and 10% Owner of Greenwich LifeSciences Inc (GLSI, Financial), purchased 1,500 shares of the company. This transaction was documented in an SEC Filing. Following this acquisition, the insider now owns a total of 5,536,102 shares in the company.
Greenwich LifeSciences Inc (GLSI, Financial) is a biopharmaceutical company focused on the development of immunotherapies for breast cancer. The company's primary product candidate is in various stages of clinical trials, aimed at preventing the recurrence of breast cancer in patients.
Over the past year, Snehal Patel has been actively increasing his stake in the company, with a total of 270,425 shares purchased and no shares sold. This recent purchase aligns with a broader trend of insider buying at Greenwich LifeSciences Inc, where there have been 23 insider buys and no insider sells over the past year.
Shares of Greenwich LifeSciences Inc were priced at $14.63 on the day of the transaction, placing the company's market cap at approximately $185.997 million. The company's valuation metrics, including price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are accessible for further details.
The insider's consistent buying activity may be of interest to investors, especially considering the company's focus on innovative cancer treatments. For a visual representation of insider trends, see the image below:
For more detailed information on the valuation of Greenwich LifeSciences Inc, investors may refer to the GF Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
